Mayne Pharma market update
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Mayne Pharma Group Ltd. has released a market update for the first half of the fiscal year, detailing expected revenue and EBITDA growth compared to the previous year. This growth is attributed to strong performance in the Women’s Health portfolio and improved margins in Dermatology. The preliminary results are pending final auditor review and board approval, with full details to be disclosed later this month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- 2024 AGM presentation and business update
- Mayne Pharma reports FY24 financial results
- 2024 Full Year Results Investor Presentation
- 2024 Full Year Results Media Release
- Appendix 4E and Full Year Statutory Accounts
Later from Mayne Pharma
- Mayne Pharma enters Scheme Implementation Deed with Cosette
- 2025 Half Year Media Release
- 2025 Half Year Investor Presentation
- Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
- Response to ASX Query
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma